VistaGen Therapeutics, Inc. VTGN

VTGN Company Overview

VistaGen Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing neuropsychiatric and neurological therapeutics, with an emphasis on therapies for anxiety, depression, and related central nervous system disorders. The company operates within the biopharmaceutical industry and concentrates primarily on drug development programs targeting large unmet mental health markets. VistaGen’s core value proposition centers on rapid-acting therapies designed to address limitations associated with conventional psychiatric medications, particularly selective serotonin reuptake inhibitors and benzodiazepines.

The company’s principal development programs include intranasal pherine-based therapeutics and oral neuroactive compounds intended for conditions such as social anxiety disorder, major depressive disorder, and adjustment disorder with anxiety. VistaGen traces its origins to stem-cell and regenerative medicine research before transitioning toward neuropsychiatric therapeutics through strategic acquisitions, licensing agreements, and internal development initiatives. Its positioning is differentiated by its focus on non-systemic intranasal therapies designed to act through peripheral neural pathways rather than traditional systemic absorption mechanisms.